long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial https://t.co/83ebyj2yf2 @eaneurology @ihs_official @messoudashina @rigshospitalet #erenumab #aimovig #migraine #neurology #brain